Lurosetron | GR 87442 | serotonin 5HT3 receptor antagonist | CAS#128486-54-4

MedKoo Cat#: 126639 | Name: Lurosetron

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lurosetron (GR 87442) is a serotonin 5HT3 receptor antagonist.

Chemical Structure

Lurosetron

CAS#128486-54-4 (free base)

Theoretical Analysis

MedKoo Cat#: 126639

Name: Lurosetron

CAS#: 128486-54-4 (free base)

Chemical Formula: C17H17FN4O

Exact Mass: 312.1386

Molecular Weight: 312.35

Elemental Analysis: C, 65.37; H, 5.49; F, 6.08; N, 17.94; O, 5.12

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

143486-90-2 (mesylate) 128486-54-4 (free base)

Synonym

Lurosetron; GR 87442; GR-87442; GR87442

IUPAC/Chemical Name

6-fluoro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one

InChi Key

NUMKWGDDRWJQMY-UHFFFAOYSA-N

InChi Code

InChI=1S/C17H17FN4O/c1-10-13(20-9-19-10)8-22-7-6-14-15(17(22)23)11-4-3-5-12(18)16(11)21(14)2/h3-5,9H,6-8H2,1-2H3,(H,19,20)

SMILES Code

CN1C2=C(C3=C1C(F)=CC=C3)C(=O)N(CC4=C(C)NC=N4)CC2

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 312.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Ouyang W, Zhao X, Lu S, Wang Z. Prevalence of monoclonal gammopathy of uncertain significance in chronic myeloid leukemia: A case report. Medicine (Baltimore). 2018 Nov;97(44):e13103. doi: 10.1097/MD.0000000000013103. PubMed PMID: 30383696. 2: Raut CP, Espat NJ, Maki RG, Araujo DM, Trent J, Williams TF, Purkayastha DD, DeMatteo RP. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial. JAMA Oncol. 2018 Nov 1:e184060. doi: 10.1001/jamaoncol.2018.4060. [Epub ahead of print] PubMed PMID: 30383140. 3: Gadelha EPN, Ramasawmy R, da Costa Oliveira B, Moraes Rocha N, de Oliveira Guerra JA, Allan Villa Rouco da Silva G, Gabrielle Ramos de Mesquita T, Chrusciak Talhari Cortez C, Chrusciak Talhari A. An open label randomized clinical trial comparing the safety and effectiveness of one, two or three weekly pentamidine isethionate doses (seven milligrams per kilogram) in the treatment of cutaneous leishmaniasis in the Amazon Region. PLoS Negl Trop Dis. 2018 Oct 31;12(10):e0006850. doi: 10.1371/journal.pntd.0006850. [Epub ahead of print] PubMed PMID: 30379814. 4: Wybraniec MT, Wróbel W, Wilkosz K, Wrona K, Bula K, Mizia-Stec K. Pharmacological Cardioversion With Antazoline in Atrial Fibrillation: The Results of the CANT Study. J Am Heart Assoc. 2018 Oct 16;7(20):e010153. doi: 10.1161/JAHA.118.010153. PubMed PMID: 30371270. 5: Morandi F, Amoroso L, Dondero A, Castriconi R, Parodi S, Luksch R, Casale F, Castellano A, Garaventa A, Moretta A, Bottino C, Ponzoni M, Corrias MV. Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma. Oncoimmunology. 2018 Jul 30;7(9):e1468953. doi: 10.1080/2162402X.2018.1468953. eCollection 2018. PubMed PMID: 30357053; PubMed Central PMCID: PMC6197024. 6: Bennett C, Mohammed F, Álvarez-Ciara A, Nguyen MA, Dietrich WD, Rajguru SM, Streit WJ, Prasad A. Neuroinflammation, oxidative stress, and blood-brain barrier (BBB) disruption in acute Utah electrode array implants and the effect of deferoxamine as an iron chelator on acute foreign body response. Biomaterials. 2018 Oct 18;188:144-159. doi: 10.1016/j.biomaterials.2018.09.040. [Epub ahead of print] PubMed PMID: 30343257. 7: Shu Y, Yang W, Zhang X, Xu X. Recurrent chronic myeloid leukemia with t (9;22;16) (q34; q11; p13) treated by nilotinib: A case report. Medicine (Baltimore). 2018 Oct;97(42):e12875. doi: 10.1097/MD.0000000000012875. PubMed PMID: 30335005. 8: Kuddushi M, Patel NK, Rajput S, Shah A, El Seoud OA, Malek NI. Thermo-Switchable de Novo Ionic Liquid-Based Gelators with Dye-Absorbing and Drug-Encapsulating Characteristics. ACS Omega. 2018 Sep 30;3(9):12068-12078. doi: 10.1021/acsomega.8b01984. Epub 2018 Sep 27. PubMed PMID: 30320287; PubMed Central PMCID: PMC6175494. 9: Yam C, Murthy RK, Rauch GM, Murray JL, Walters RS, Valero V, Brewster AM, Bast RC Jr, Booser DJ, Giordano SH, Esteva FJ, Yang W, Hortobagyi GN, Moulder SL, Arun B. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β. Invest New Drugs. 2018 Oct 11. doi: 10.1007/s10637-018-0672-z. [Epub ahead of print] PubMed PMID: 30311036. 10: Yu T, Wu C, Zhu C, He Y, Yang D, Cheng Y, Gao X. Oral Administration of Liposome-Apatinib and Locally Delivery of Docetaxel/MPEG-PCL by Fibrin Glue Synergistically Improve Therapeutic Effect in Colorectal Cancer. J Biomed Nanotechnol. 2018 Dec 1;14(12):2077-2091. doi: 10.1166/jbn.2018.2651. PubMed PMID: 30305215. 11: Olivito F, Costanzo P, Di Gioia ML, Nardi M, M O, Procopio A. Efficient synthesis of organic thioacetates in water. Org Biomol Chem. 2018 Nov 7;16(41):7753-7759. doi: 10.1039/c8ob01896k. Epub 2018 Oct 9. PubMed PMID: 30299446. 12: Wu W, Hou B, Tang C, Liu F, Yang J, Pan T, Si K, Lu D, Wang X, Wang J, Xiong X, Liu J, Xie C. (+)-Usnic Acid Inhibits Migration of c-KIT Positive Cells in Human Colorectal Cancer. Evid Based Complement Alternat Med. 2018 Sep 12;2018:5149436. doi: 10.1155/2018/5149436. eCollection 2018. PubMed PMID: 30298093; PubMed Central PMCID: PMC6157178. 13: Bono S, Dello Sbarba P, Lulli M. Sensitivity to imatinib of KCL22 chronic myeloid leukemia cell survival/growth and stem cell potential under glucose shortage. Data Brief. 2018 Sep 19;20:1901-1904. doi: 10.1016/j.dib.2018.09.041. eCollection 2018 Oct. PubMed PMID: 30294641; PubMed Central PMCID: PMC6168789. 14: Sung Y, Kim MH, Cho E. Successful hyaluronic acid filler injection in a chronic myeloid leukemia patient taking imatinib mesylate. J Cosmet Laser Ther. 2018 Oct 4:1-2. doi: 10.1080/14764172.2018.1525745. [Epub ahead of print] PubMed PMID: 30285513. 15: Urquhart DM, Wluka AE, van Tulder M, Heritier S, Forbes A, Fong C, Wang Y, Sim MR, Gibson SJ, Arnold C, Cicuttini FM. Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain: A Randomized Clinical Trial. JAMA Intern Med. 2018 Oct 1. doi: 10.1001/jamainternmed.2018.4222. [Epub ahead of print] PubMed PMID: 30285054. 16: Zhang Q, Xu J, Qian Y, Chen L, Li Q, Xu K, Chen M, Sun L, He Z, Sun X, Wang Y, Xu H, Xu Z. Association of Imatinib Plasma Concentration and Single Nucleotide Polymorphisms with Adverse Drug Reactions in Patients with Gastrointestinal Stromal Tumors. Mol Cancer Ther. 2018 Oct 3. pii: molcanther.0498.2018. doi: 10.1158/1535-7163.MCT-18-0498. [Epub ahead of print] PubMed PMID: 30282814. 17: Malaekeh-Nikouei B, Rezaee M, Gholami L, Sanjar Mousavi N, Kazemi Oskuee R. Synthesis, characterization and evaluation of transfection efficiency of dexamethasone conjugated poly(propyleneimine) nanocarriers for gene delivery#(). Pharm Biol. 2018 Dec;56(1):519-527. doi: 10.1080/13880209.2018.1517183. PubMed PMID: 30270694; PubMed Central PMCID: PMC6171438. 18: Makhtar SM, Husin A, Baba AA, Ankathil R. Genetic variations in influx transporter gene SLC22A1 are associated with clinical responses to imatinib mesylate among Malaysian chronic myeloid leukaemia patients. J Genet. 2018 Sep;97(4):835-842. PubMed PMID: 30262695. 19: Sorrenti V, Pittalà V, Romeo G, Amata E, Dichiara M, Marrazzo A, Turnaturi R, Prezzavento O, Barbagallo I, Vanella L, Rescifina A, Floresta G, Tibullo D, Di Raimondo F, Intagliata S, Salerno L. Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines. Eur J Med Chem. 2018 Oct 5;158:937-950. doi: 10.1016/j.ejmech.2018.09.048. Epub 2018 Sep 17. PubMed PMID: 30261468. 20: Sood A, Sinha P, Raman DK, Sinha A. Imatinib-induced IgA Pemphigus: Subcorneal Pustular Dermatosis Type. Indian Dermatol Online J. 2018 Sep-Oct;9(5):331-333. doi: 10.4103/idoj.IDOJ_331_17. PubMed PMID: 30258803; PubMed Central PMCID: PMC6137662.